NCT04364139View on ClinicalTrials.gov

African American Study of Kidney Disease and Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

1,094

Participants

Timeline

Start Date

February 1, 1995

Primary Completion Date

September 30, 2001

Study Completion Date

June 30, 2007

Conditions
Hypertensive NephrosclerosisChronic Renal Insufficiency
Interventions
OTHER

MAP goal less than or equal to 92 mm Hg

Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg

OTHER

MAP goal 102-107 mm Hg

Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg

DRUG

Ramipril

An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d

DRUG

Amlodipine

A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d

DRUG

Metoprolol

A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT04364139 - African American Study of Kidney Disease and Hypertension | Biotech Hunter | Biotech Hunter